Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Asthma
•
Allergic Rhinitis and Conjunctivitis
Are there best practices for integrating pollen, wildfire smoke, and AQI data into asthma/allergic rhinitis action plans?
Related Questions
Is there a specific group of children that you start on AIT for prevention of asthma?
Should a patient on medium-dose ICS/LABA with normal PFTs, but who shows a greater than 10% decrease in FEV1 if their PFTs are done after 24 hours off their inhaler, be started on a biologic?
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
Have you experienced any issues with Alvesco inhalers getting clogged repeatedly?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?
How do you address the discrepancy between traditional allergy skin testing and the Rinkel skin test results?
Do you plan to use benralizumab to treat acute exacerbations of asthma or COPD associated with eosinophilia?
If a child 4 years of age or younger has respiratory symptoms consistent with asthma, are you diagnosing asthma or using different terminology such as bronchiolitis or reactive airway disease?
Do you consider the efficacy of different nasal sprays when prescribing for allergic rhinitis or conjunctivitis?
Do you generally favor nebulizers, HFAs or other devices in children aged 5 and younger with asthma?
